 |
|
Featured Clinical Trials Supported by the National Cancer Institute
Today, hundreds of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials featured in the NCI Cancer Bulletin and demonstrates the breadth of clinical cancer research supported by the NCI.
To find other cancer trials open to enrollment:
- Call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the basic PDQ search form to look online for trials listed in NCI's clinical trials database. The top of the form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call the National Cancer Institute’s Clinical Studies Support Center at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
1. Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.
2. Testing Satraplatin in Advanced Prostate Cancer
(Posted: 10/20/2009) - In this clinical trial, men with androgen-independent metastatic prostate cancer that has progressed after first-line chemotherapy will be treated with satraplatin and prednisone.
3. Targeting HER2 in the Treatment of Ductal Carcinoma in Situ
(Posted: 10/06/2009) - In this clinical trial, women with HER2-positive DCIS will be treated with lumpectomy followed by whole-breast radiation therapy; half of the women will also receive two doses of trastuzumab during their radiation treatment.
4. Comparing Drug Regimens for Diffuse Large B-cell Lymphoma
(Posted: 09/22/2009) - In this trial, patients with previously untreated diffuse large B-cell lymphoma will be randomly assigned to receive either the R-CHOP regimen or EPOCH-R regimen for 6 to 8 cycles.
5. Testing a New Drug in Advanced BRCA-related Cancer
(Posted: 09/08/2009) - In this clinical trial, women with advanced breast or ovarian cancer who carry a known BRCA gene mutation or who have a strong family history of these diseases (and are, therefore, likely to carry such a mutation) will be treated with a new drug called AZD2281 (olaparib) together with the chemotherapy drug carboplatin.
1 2 3 4 Next >
|
|
|
